Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics (the study of an organism’s hereditary information encoded in its DNA), proteomics (study of structures and functions of proteins) and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissues.
Four members comprise Biosciences management team – each bringing with him valuable experience to the laboratory. Richard T. Schumacher, founder of the company, has served as director since 1978. Among other accomplishments and jobs, Schumacher worked as the director of Infections Disease Services for Clinical Sciences Laboratory for two years; served as chairman of the board of Boston Biomedica for nine years; and was employed by the Center for Blood Research.
Edward H. Myles first joined Pressure Biosciences as vice president of finance and CFO in 2006, and is now senior vice president of finance and CFO. He has worked as a controller for EMD Pharmaceuticals, an affiliate of Merck; worked in the healthcare investment banking group of SG Cowen Securities; and was corporate controller of Boston Biomedica, among other positions.
Dr. Nathan P. Lawrence, Ph.D. served as director of Research and Development until his promotion to vice president of Marketing and Business Development in 2006. Dr. Lawrence is responsible for the development of protocols based on PCT, and for the development of nucleic acid-based diagnostic assays. He has held several positions in Research and Development, and Manufacturing at Becton Dickinson and Gene Trak Systems.
Dr. Alexander Lazarev, Ph.D. joined Pressure Biosciences in 2006 as director of Research and Development, and advanced to vice president of Research and Development last year. He has worked at the Barnett Institute of Chemical and Biological Analysis at Northeastern University; director of New Technology Development at Proteome Systems, Inc.; and held several senior research positions at Genomic Solutions, Inc. and PhytoChem Technologies, Inc.
Let us hear your thoughts: Pressure BioSciences, Inc. Message Board
